Read more about FDA Approves Olaparib for Ovarian Cancer
FDA Approves Olaparib for Ovarian Cancer
(December 19, 2014) The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Olaparib (Lynparza) for advanced, BRCA-mutated ovarian cancer, the first approval of a drug in the PARP (poly...